Publications by authors named "J T Kurnick"

Article Synopsis
  • The delivery of therapeutic molecules often causes unwanted toxicity to normal cells, but this issue can be avoided by splitting the therapeutic molecule into two inactive parts that only combine at the target site.
  • The process involves using target-specific molecules to create a template that helps bring these inactive components together, enhancing the assembly of a functional molecule for recognition by antibodies.
  • Researchers showcased the feasibility of this method using modified oligonucleotides to assemble a mimotope recognized by the antibody trastuzumab, while also addressing potential limitations related to the need for excess template molecules.
View Article and Find Full Text PDF

Purpose: Although the role of integrins has been described in a variety of diseases, these roles seem to be distinct. To date, no study has attempted to provide links to the various pathways by which such integrins can be involved in these diverse disease settings. The purpose of this review was to address this gap in our knowledge with the hypothesis that there is, in fact, a common pathway by which integrins may function.

View Article and Find Full Text PDF

In an effort to enhance antigen-specific T cell recognition of cancer cells, we have examined numerous modulators of antigen-expression. In this report we demonstrate that twelve different Hsp90 inhibitors (iHsp90) share the ability to increase the expression of differentiation antigens and MHC Class I antigens. These iHsp90 are active in several molecular and cellular assays on a series of tumor cell lines, including eleven human melanomas, a murine B16 melanoma, and two human glioma-derived cell lines.

View Article and Find Full Text PDF

Although a series of melanoma differentiation antigens for immunotherapeutic targeting has been described, heterogeneous expression of antigens such as Melan-A/MART-1 and gp100 results from a loss of antigenic expression in many late stage tumors. Antigen loss can represent a means for tumor escape from immune recognition, and a barrier to immunotherapy. However, since antigen-negative tumor phenotypes frequently result from reversible gene regulatory events, antigen enhancement represents a potential therapeutic opportunity.

View Article and Find Full Text PDF

The highly diverse heterodimeric surface T cell receptor (TCR) gives the T lymphocyte its specificity for MHC-bound peptides needed to initiate antigen-recognition. In normal peripheral blood, spleen and lymph nodes, the TCR repertoire of the T lymphocytes is usually polyclonal. However, in malignancies such as leukemias, as well as in lymphoproliferative diseases of mature T cells, the TCR is a reflection of the clonality of the malignant cells and is therefore monoclonal.

View Article and Find Full Text PDF